<DOC>
	<DOCNO>NCT02489318</DOCNO>
	<brief_summary>The purpose study determine addition apalutamide ADT provide superior efficacy improve radiographic progression-free survival ( rPFS ) overall survival ( OS ) participant mHSPC .</brief_summary>
	<brief_title>A Study Apalutamide ( JNJ-56021927 , ARN-509 ) Plus Androgen Deprivation Therapy ( ADT ) Versus ADT Participants With mHSPC</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled , multinational , multicenter study apalutamide participant mHSPC . The study consist 4 Phases : Screening Phase ( 28 day randomization ) , Treatment Phase ( 28 day treatment cycle disease progression occurrence unacceptable treatment related toxicity ) , End Treatment Phase ( 30 day last dose study drug ) , Survival Follow Phase . In event positive study result either interim analysis final analysis , participant treatment Phase opportunity enroll Open-label Extension Phase , allow participant receive active drug ( apalutamide ) approximately 3 year . The radiographic progression-free survival overall survival evaluate . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Diagnosis prostate adenocarcinoma confirm investigator Metastatic disease document great equal ( &gt; = ) 1 bone lesion 99mTc bone scan . Participants single bone lesion must confirmation bone metastasis compute tomography ( CT ) magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) grade 0 1 Participants receive docetaxel treatment must meet following criterion : ) Received maximum 6 cycle docetaxel therapy mHSPC ; b ) Received last dose docetaxel &lt; =2 month prior randomization ; c ) Maintained response docetaxel stable disease well , investigator assessment image PSA , prior randomization Other allow prior treatment mHSPC : ) Maximum 1 course radiation surgical intervention ; radiation therapy metastatic lesion must complete prior randomization ; b ) Less equal ( &lt; = ) 6 month ADT prior randomization Allowed prior treatment localize prostate cancer ( treatment must complete &gt; = 1 year prior randomization ) ) &lt; = 3 year total ADT ; b ) All form prior therapy include radiation therapy , prostatectomy , lymph node dissection , systemic therapy Pathological find consistent small cell , ductal neuroendocrine carcinoma prostate Known brain metastasis Lymph node sit metastasis Visceral ( ie , liver lung ) metastases sites metastasis Other prior malignancy less equal 5 year prior randomization exception squamous basal cell skin carcinoma noninvasive superficial bladder cancer Prior treatment next generation antiandrogens CYP17 inhibitor , immunotherapy radiopharmaceutical agent prostate cancer History seizures medication know low seizure threshold</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>JNJ-56021927</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
	<keyword>ARN-509</keyword>
	<keyword>Apalutamide</keyword>
	<keyword>TITAN</keyword>
	<keyword>Metastatic Hormone-sensitive Prostate Cancer</keyword>
</DOC>